Print Friendly, PDF & Email

NCT/Study#

NCT04613596 /

849-007

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: